Contact: Mark K. Slifka
Location: Beaverton, OR
Email: info@najittech.com
Tel: (503) 346-5483
Website: http://www.najittech.com/

Company Profile

Industry Sector: Military and Neglected Disease Vaccine Market

Company Overview: Najít Technologies, Inc. (NTI) is dedicated to the development of safe and effective vaccines for emerging and re-emerging infectious diseases. Our proprietary vaccine technology is designed to benefit the American Warfighter as well as previously underserved and vulnerable populations, such as the very young, the elderly, and the immunocompromised. With increased safety and immunogenicity, our vaccine platform better serves the general population. Our strategy is to develop vaccines that fit the unmet needs of these market segments in addition to military and civilian travelers who need safe but highly effective vaccines against potentially life-threatening infectious diseases in endemic countries.

Target Market(s):
U.S. Military
International travelers
Vulnerable populations: Infants, Elderly, & Immunocompromised

Key Value Drivers

Technology*: HydroVax™ technology is based on the simple, yet highly effective approach of using hydrogen peroxide (H_2O_2) to inactivate viruses and bacteria for vaccine development. The key to the HydroVax™ platform is that it uses site-directed oxidation to inactivate microorganisms without damaging important neutralizing epitopes or reducing overall immunogenicity. HydroVax™ is a broadly applicable platform technology that we believe will usher in a new era of advanced vaccine development.

Competitive Advantage: In side-by-side comparisons, HydroVax™ outperforms other forms of virus inactivation for vaccine preparation. Unlike other inactivating agents such as formaldehyde or betapropiolactone (BPL) that are in the public domain, the use of H_2O_2 for vaccine development represents patented technology with a strong IP position. Oxidation of nucleic acids is the mechanism of action underlying HydroVax™ technology and this differs substantially from formaldehyde (a crosslinking agent) and BPL (an alkylating agent), thus providing a significantly improved alternative to these older and outdated methodologies.

Plan & Strategy: Seeking a strategic partner to develop/co-develop new vaccines.

Management

Leadership:
Mark Slifka, PhD, President and CSO
Ian Amanna, PhD, Senior Vice President for Research
Samantha Harmon, MBA, Senior Director of Accounting & Administration

Key Consultants and Advisors:
Hitendra (Vijay) Jethwa, MBA PhD, GMP Manufacturing Quality Assurance, Biologics Consulting Group
Peter Patriarca, MD, Clinical Regulatory Compliance, Immuno-VAX, LLC
Michael Phillips, JD, Corporate and Business Law, Davis Wright Tremaine, LLP
Barry Davison, JD, Patent Law, David Wright Tremaine, LLP

Product Pipeline

We have optimized cGMP manufacturing parameters for several vaccines. An important advantage of this platform technology is its ability to rapidly incorporate new vaccine targets to our growing product pipeline and combine viral antigens to generate vaccines against entire virus families.



*Abbreviations: CHIKV; chikungunya virus, WNV; West Nile virus, YFV; yellow fever virus, Pan-alphavirus; multivalent vaccine designed to protect against all major clinically relevant alphaviruses

Keywords: vaccine manufacturing; emerging and re-emerging infectious disease; military and traveler's market; flaviviruses; alphaviruses; influenza